Mayinglong Pharmaceutical Group Co., Ltd. (SHA:600993)
China
· Delayed Price · Currency is CNY 26.11
+0.21 (0.81%)
Apr 29, 2026, 3:00 PM CST
SHA:600993 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 614.72 | 605.71 | 528.09 | 443.25 | 478.57 | 464.59 | Upgrade
|
| Depreciation & Amortization | 94.39 | 94.39 | 73.33 | 80.56 | 78.51 | 68.57 | Upgrade
|
| Other Amortization | 3.98 | 3.98 | 13.31 | 9.52 | 9.83 | 9.22 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.09 | 0.09 | -0.02 | -5.65 | 0.29 | 0.79 | Upgrade
|
| Asset Writedown & Restructuring Costs | 14.26 | 14.26 | 5.4 | 0.09 | 0.06 | 0.15 | Upgrade
|
| Loss (Gain) From Sale of Investments | -35.18 | -35.18 | -13.81 | -91.91 | -2.86 | -54.31 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | 8.27 | 3.93 | 9.93 | 3.06 | Upgrade
|
| Other Operating Activities | 86.16 | 9.84 | 30.63 | 35.36 | 18.52 | 26.47 | Upgrade
|
| Change in Accounts Receivable | -191.45 | -191.45 | -193.98 | 148.03 | -356.2 | 231.67 | Upgrade
|
| Change in Inventory | -44.36 | -44.36 | -8.7 | 55.32 | -26.26 | -46.37 | Upgrade
|
| Change in Accounts Payable | 148.52 | 148.52 | 61.32 | -75.45 | 137.86 | -105.32 | Upgrade
|
| Change in Other Net Operating Assets | - | - | - | -1.12 | -0.77 | -0.32 | Upgrade
|
| Operating Cash Flow | 685.77 | 600.44 | 497.61 | 604.07 | 341.85 | 597.17 | Upgrade
|
| Operating Cash Flow Growth | 15.94% | 20.66% | -17.62% | 76.70% | -42.75% | 111.02% | Upgrade
|
| Capital Expenditures | -89.61 | -119.37 | -203.85 | -248.36 | -75.01 | -65.1 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.5 | 0.5 | 0.92 | 3.61 | 0.46 | 0.58 | Upgrade
|
| Divestitures | 0.45 | 0.45 | - | -0.56 | - | 4 | Upgrade
|
| Investment in Securities | -756.3 | -743.36 | -60.72 | 675.91 | -574.13 | -36.59 | Upgrade
|
| Other Investing Activities | 0.07 | 0.07 | - | 17.68 | 29.92 | 34.07 | Upgrade
|
| Investing Cash Flow | -844.89 | -861.72 | -263.65 | 448.27 | -618.76 | -63.05 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | - | 78 | Upgrade
|
| Long-Term Debt Issued | - | 14 | 44.6 | 58.6 | 488.31 | - | Upgrade
|
| Total Debt Issued | 14 | 14 | 44.6 | 58.6 | 488.31 | 78 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -123 | Upgrade
|
| Long-Term Debt Repaid | - | -156.45 | -91.91 | -429.95 | -127.47 | -32.81 | Upgrade
|
| Total Debt Repaid | -136.55 | -156.45 | -91.91 | -429.95 | -127.47 | -155.81 | Upgrade
|
| Net Debt Issued (Repaid) | -122.55 | -142.45 | -47.31 | -371.35 | 360.84 | -77.81 | Upgrade
|
| Common Dividends Paid | -269.53 | -269.65 | -177.28 | -162.71 | -165.04 | -124.5 | Upgrade
|
| Other Financing Activities | -63.39 | -69.28 | -50.74 | -45.1 | -17.62 | 32.66 | Upgrade
|
| Financing Cash Flow | -455.47 | -481.38 | -275.33 | -579.16 | 178.18 | -169.64 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.45 | -0.2 | 0.24 | 0.26 | 1.24 | -0.6 | Upgrade
|
| Net Cash Flow | -615.05 | -742.87 | -41.13 | 473.43 | -97.49 | 363.88 | Upgrade
|
| Free Cash Flow | 596.17 | 481.07 | 293.76 | 355.7 | 266.84 | 532.07 | Upgrade
|
| Free Cash Flow Growth | 51.32% | 63.76% | -17.41% | 33.30% | -49.85% | 123.96% | Upgrade
|
| Free Cash Flow Margin | 15.25% | 12.44% | 7.88% | 11.34% | 7.55% | 15.72% | Upgrade
|
| Free Cash Flow Per Share | 1.38 | 1.12 | 0.68 | 0.83 | 0.62 | 1.24 | Upgrade
|
| Cash Income Tax Paid | 343.71 | 310.83 | 328.43 | 323.88 | 308.24 | 288.92 | Upgrade
|
| Levered Free Cash Flow | 237.51 | 94.21 | 186.16 | 129.78 | 263.3 | 281.25 | Upgrade
|
| Unlevered Free Cash Flow | 237.51 | 94.21 | 190.77 | 140.32 | 270.61 | 287.63 | Upgrade
|
| Change in Working Capital | -92.66 | -92.66 | -147.61 | 128.91 | -251 | 78.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.